Pfizer-Astellas’ Combo Long-Term Efficacy in First-Line Treatment of Urothelial Cancer

 

• Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of la/mUC

• At nearly 30 months of follow-up in the Phase 3 EV-302 trial, the combination doubled median overall survival and progression-free survival compared to chemotherapy, with no new safety signals identified

https://www.businesswire.com/news/home/20250210184062/en